| Document |
Document Title |
|
WO/2004/089968A1 |
1-ß-D-Arabinofuranosyluracil in a 3',5'-hydroxy-protected form is reacted with a trifluoromethanesulfonylating agent in the presence of an organic base to convert it into a 2'-triflate form, and this compound is reacted with a fluorinat...
|
|
WO/2004/090154A2 |
The present invention provides tagged acyl phosphate probes ('TAPPs'), and methods of their preparation and use. The subject methods and compositions can provide enhanced simplicity and accuracy in identifying changes in the presence, am...
|
|
WO/2004/086949A2 |
A method is provided for assessing allelic losses and hypermethylation of genes in CpG tumor promotor region on specific chromosomal regions in cancer patients, including melanoma, neuroblastoma breast, colorectal, and prostate cancer pa...
|
|
WO/2004/088312A2 |
Library comprising a plurality of tagged non-peptide ligands of formula (I): (Lig JL)m L(JT Tag) m (JTL(JLLig)m)p including and salts thereof comprising one or a plurality of same or different ligand moieties Lig each linked to a one or ...
|
|
WO/2004/087939A1 |
The invention provides a process for the preparation of fludarabine phosphate from 2-fluoroadenine and 9-β-D-arabinofuranosyl-uracil using Enterobacter aerogenes (EBA). 2-Fluoroadenine is reacted with 9-β-D-arabinosyl-uracile in a wate...
|
|
WO/2004/085454A1 |
Oligonucleotide comprising at least one internucleotide phosphorus atom protected with a group of formula -XaSiR3R4R5 provided. Xa represent 0 or S, and R3, R4 and R5 each independently are optionally substituted hydrocarbyl groups, sele...
|
|
WO/2004/085453A1 |
The present invention relates to methods for the synthesis and purification of cyclic nucleotide derivatives. The present invention provides a method for separating a cyclic nucleotide derivative from a mixture resulting from a chemical ...
|
|
WO/2004/083258A2 |
The present invention provides branched water-soluble polymers that allow two or more water-soluble polymers to be conjugated to another species. The branched polymers provide access to therapeutic agents that are conjugated at a single ...
|
|
WO/2004/083228A1 |
Compounds represented by the following general formula [I] or pharmaceutically acceptable salts thereof and antitumor agents containing the same as the active ingredient: [I] wherein R represents pyridyl, furyl or thienyl optionally havi...
|
|
WO/2004/082618A2 |
The present invention provides a method for the preparation of 5-azacytidine, wherein 5-azacytidine is represented by the structure: The method involves the silylation of 5-azacytosine, followed by the coupling of silylated 5-azacytosine...
|
|
WO/2004/083186A1 |
A therapeutic agent for chronic hepatitis C which contains either a compound represented by the formula (1) (wherein R1 represents hydrogen or ribofuranosyl; and R2 represents hydrogen or a hydroxy-protecting group) or a salt thereof. It...
|
|
WO/2004/084453A2 |
The present invention relates to the synthesis of 2’-deoxy-β-L-thymidine, 2’deoxy-β-L-uridine and 2’-deoxy-β-L-cytidine, and their derivatives, such as the 3’-Oacyl or 3’,5’-O-diacyl prodrugs, including the 3’-O-L-am...
|
|
WO/2004/082822A2 |
The invention includes methods for isolating crystalline Form I of 5-azacytidine substantially free of other forms, wherein 5-azacytidine is represented by the formula: The invention also includes pharmaceutical compositions comprising F...
|
|
WO/2004/082619A2 |
The invention provides novel polymorphic and pseudopolymorphic crystalline forms of 5-azacytidine, along with methods for preparing said forms, wherein 5-azacythidine is represented by the formula (I). The invention also includes pharmac...
|
|
WO/2004/083155A2 |
The subject of the present invention are specific lipidesters of halogenated-adenine nucleotides and the use of such lipidesters in the treatment of tumors.
|
|
WO/2004/080466A1 |
Cytidine analogs, their prodrugs and/or metabolites are employed as pharmaceutically active compounds for treatment of diseases responsive to such compounds. Particularly preferred diseases include viral diseases (e.g., HCV infection) an...
|
|
WO/2004/078993A2 |
A method of making didanosine (ddI) including the steps of: (a) obtaining an enzyme expressing ddA deaminase activity; (b) immobilizing the enzyme onto an insoluble support; (c) contacting the enzyme with a dideoxyadenosine (ddA) solutio...
|
|
WO/2004/078933A2 |
An amino acid sequence Arg-Lys-Met-Leu-Lys-Ser-Thr-Arg-Arg-Gln-Arg-Arg (SEQ ID NO: 1) functions as a protein transduction domain (PTD) and is capable of delivering small molecules, proteins, and nucleic acids to an intracellular compartm...
|
|
WO/2004/078994A2 |
The invention provides a method useful for detection of genetic disorders. The method comprises determining the sequence of alleles of a locus of interest, and quantitating a ratio for the alleles at the locus of interest, wherein the ra...
|
|
WO/2004/079011A1 |
The invention provides a method useful for detection of genetic disorders. The method comprises determining the sequence of alleles of a locus of interest, and quantitating a ratio for the alleles at the locus of interest, wherein the ra...
|
|
WO/2004/076472A1 |
It is intended to provide a novel monomer unit by which Z type DNA can be more effectively stabilized, a reagent for integrating this monomer unit into an oligonucleotide, and a method of stabilizing Z type DNA by using the reagent. Name...
|
|
WO/2004/074503A2 |
The present invention relates to nucleic acid sequencing methods, kits and reagents, and more particularly to methods of sequencing nucleic acid which employ a nucleic acid processing enzyme and one or more nucleotide analogues that are ...
|
|
WO/2004/074300A2 |
The present invention discloses novel and improved nucleosidic and nucleotidic compounds that are useful in the light-directed synthesis of oligonucleotides, as well as, methods and reagents for their preparation. These compounds are cha...
|
|
WO/2004/072090A1 |
A process is provided for the preparation of branched-chain ribonucleosides of formula (I) from the 1,2- anhydro derivatives of fomula (II). The compounds of fomula (I) are inhibitors of HCV polymerase useful in the treatment of HCV infe...
|
|
WO/2004/072234A2 |
A process of manufacturing protected nucleosides comprises reacting a nucleoside with a protecting reagent in the presence of a regioselective activator to produce a regioselectively protected nucleoside. In some embodiments of the inven...
|
|
WO/2004/072297A2 |
The present invention relates to improved methods of detecting a target using a labeled substrate or substrate analog. The methods comprise reacting the substrate or substrate analog in an enzyme-catalyzed reaction which produces a label...
|
|
WO/2004/069261A1 |
A process for producing an antiherpesvirus preparation for external use which contains as an active ingredient a 5-[(E)-2-halogenovinyl]arabinofuranosyluracil represented by the following general formula (I), characterized in that in any...
|
|
WO/2004/069856A1 |
The present invention relates to a new process for the preparation of compounds of general formula (I) which are inhibitors of purine nucleoside phosphorylases (PNP), purine phosphoribosyltransferases (PPRT), 5'-methylthioadenosine phosp...
|
|
WO/2004/070052A2 |
Compounds and methods are provided for a single-pot covalent attachment of a label to nucleic acids comprising forming a covalently attachable labeling reagent for alkylating the molecule. Then, combining the covalently attachable labeli...
|
|
WO2004016805A9 |
The invention relates to a class of soft or semi-soft CpG immunostimulatory oligonucleotides that are useful for stimulating an immune response.
|
|
WO/2004/069171A2 |
Compounds have been designed to inhibit the action of cytochrome b5 in the physiological re-reduction of auto-oxidized hemoglobin (methemoglobin), for the purpose of increasing methemoglobin levels in the blood of patients as a treatment...
|
|
WO/2004/069855A1 |
It is intended to provide a mechanism of designing a novel enzyme activity regulator. Paying attention to a change in the conformation of an enzyme depending on a substrate, the above problem is solved by applying the relationship betwee...
|
|
WO/2004/067544A1 |
Caprazene and caprazol are prepared by hydrolysis of caprazamycin. Caprazene-1’’’-amide derivatives of the general formula (II) and caprazene-1’’’-ester derivatives of the general formula (III) are prepared from caprazene. Ca...
|
|
WO/2004/065398A2 |
An improved method of preparing a sugar modified nucleoside analog includes a protocol in which a hydroxy group of a sugar is selectively deprotected and oxidized prior to nucleophilic modification of the corresponding carbonyl group. Th...
|
|
WO/2004/065403A1 |
A process for the production of nucleosides represented by the general formula [II], characterized by subjecting a 2’, 3’, 5’-triacyloxynucleoside represented by the general formula [I] to deacylation with 0.01 to 0.5 time by mole ...
|
|
WO/2004/060902A2 |
Compounds or compositions that are inhibitors and/or ligands of nucleoside transporters; and methods of treating cancer, heart disease and stroke, as well as AIDS and other infectious diseases according to the general formula : wherein t...
|
|
WO/2004/058793A1 |
A novel nucleotide derivative showing a change in the fluorescent signal intensity depending on the corresponding base species of the counterpart chain of hybridization and occurring as a member of a single-strand nucleotide sequence, (1...
|
|
WO/2004/058391A2 |
The invention relates to a method for the synthesis of biopolymers by step-by-step construction using protected synthesis units carrying two-stage protective groups. Said two-stage protective groups are activated by a first irradiation s...
|
|
WO/2004/058393A2 |
The invention relates to a method for validating the synthesis of arrays, especially biopolymers, by constructing the same from protected and marked synthesis units in a step-by-step manner.
|
|
WO/2004/058392A2 |
The invention relates to novel photoactivatable protective groups having a quantum yield which can be significantly increased by means of an intramolecular sensitizer. The invention also relates to the use of said groups in the synthesis...
|
|
WO/2004/058792A1 |
Provided is a single-step process for the selective 3'-acylation of a ribofuranosyl 2' or 3'-branched nucleoside. These compounds are useful as antiviral agents, and in particular,can be used to treat Flaviviridae infections in a host in...
|
|
WO/2004/058791A2 |
The invention concerns novel substitution derivatives of N6-benzyladenosine having anticancer, mitotic, immunosuppressive and antisenescent properties for plant, animal and human cells. This invention also relates to the methods of prepa...
|
|
WO/2004/057316A1 |
The invention relates to a method of detecting adenosine triphosphate (ATP) involving the use of silicon oxides which are functionalised with organic molecules that can emit a macroscopically-measurable signal when in aqueous suspension ...
|
|
WO/2004/057010A2 |
A method for in vitro preparation of deoxyribonucleotides is disclosed. The deoxyribonucleotides in the present invention are converted from ribonucleotides extracted from yeast in the presence of E. coli RNA reductase and a reducing agent.
|
|
WO/2004/057011A1 |
Antibiotics caprazamycin D and caprazamycin G represented by the following general formula (I) are obtained by culturing Streptomyces sp. MK730−62F2 (Accession No. FERM BP−7218). Caprazamycins D and G show excellent antimicrobial act...
|
|
WO/2004/055199A2 |
The present invention is directed to a method for screening bloodand blood products that utilizes a specialized blood and blood p roducts storage device useful for storing and testing blood or blood products comprising a container having...
|
|
WO/2004/055198A2 |
A device for in-line blood screening and testing using biochips is disclosed. The screening methods include nucleic acid amplification techniques and antibody/antigen assays to detect target molecules and agents indicative of infectious ...
|
|
WO/2004/055034A1 |
(2S,3S,4R,5R)-2-(5-tert-butyl-[1,3,4]-oxadiazol-2-yl)-5-[6-(
4-chloro-2-fluorophenylamino)-purin-9-yl]-tetrahydrofuran-3,
4-diol in polymorphic form III.
|
|
WO/2004/055033A1 |
(2S,3S,4R,5R)-2-(5-tert-butyl-[1,3,4]-oxadiazol-2-yl)-5-[6-(
4-chloro-2-fluorophenylamino)-purin-9-yl]-tetrahydrofuran-3,
4-diol in polymorphic form IV.
|
|
WO/2004/055032A1 |
(2S,3S,4R,5R)-2-(5-tert-butyl-[1,3,4]-oxadiazol-2-yl)-5-[6-(
4-chloro-2-fluorophenylamino)-purin-9-yl]-tetrahydrofuran-3,
4-diol in polymorphic form V.
|
